Nvidia, a prominent artificial intelligence technology company, showcases interest in healthcare through launching new AI tools and partnering with Johnson & Johnson and GE Healthcare at its 2024 GTC conference. The adoption of AI in drug discovery speeds up the process while reducing costs. Nvidia's BioNeMo platform targets drug development and offers cost savings beyond that area. The company has invested $50 million in Recursion Pharmaceuticals and partnered with Roche's Genentech, Schrödinger, and others for medication development and treatment protocol improvement. AI is transforming healthcare by impacting drug development, cost reduction, and patient care through companies like Nvidia.

--- Send in a voice message: https://podcasters.spotify.com/pod/show/tonyphoang/message